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Abstract 
This is a concise review of the KDR/VEGFR2 gene, 
including expression, function, and implications of 
VEGFR2 expression in cancer. 
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The human KDR/VEGFR2 gene was cloned in 1991 
and mapped in 1992 (Terman BI et al., 1991, Terman 
BI et al., 1992). The human gene (Kdr/VEGFR2) 
maps to human chromosome 4. The mouse gene 
(Kdr/Vegfr2/Flk-1) was cloned in 1991(Matthews 
W et al., 1991). The mouse gene (Flk-1/Vegfr2) is 
located on mouse chromosome 5. 
Transcription 
In humans, the KDR gene consists of 30 exons, 
spanning 47,337 bp of DNA on the reverse strand of 
Chromosome 4. Exon 1 contains 5' UTR and exon 
30 contains 3' UTR. All 30 exons contain translated 
sequence. Three splice variants have been reported 
in Ensembl. Alternative splicing results in partial 
retention of intron 13 and an alternative stop codon, 
encoding a unique C-terminal sequence. 
Transcription factors regulating Vegfr2 expressing 
include ETS1 and ETS2 (Elvert G et al., 2003, 
Kappel A et al., 2000), EPAS1 (hypoxia inducible 
factor 2 alpha) (Elvert G et al., 2003), ETV2 
(ER71/etsrp) (Lee D et al., 2008), and OVOL2 (Kim 
JY et al., 2014). 
Protein 
Description 
The canonical form of VEGFR2 comprises 1356 
amino acids in humans and 1345 in mice. VEGFR2 
is translated into a 150 kDa protein. Glycosylation of 
the extracellular domain results in the mature form 
at the cell surface which migrates at 230 kDa via 
western blot. 
VEGFR2 is composed of three domains: an 
extracellular domain, transmembrane domain, and a 
cytosolic domain. The extracellular domain 
(including N-terminus) is composed of a signal 
peptide (aa: 1-20) and seven Ig-like subdomains (aa: 
20-764).  
The second and third Ig-like subdomains (aa: 141-
207, 224-320) facilitate binding of the principal 
VEGFR2 ligand, VEGFA (Fug G et al., 1998, 
Shinkai A et al., 1998). This is followed by a single-
pass type I transmembrane domain (aa: 765-785). 
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The intracellular region (aa: 786-1356) consists of a 
juxtamembrane domain (JMD) and kinase domain. 
Biochemical analyses by Solowiej et al. (2009) 
determined that the JMD promotes 
autophosphorylation of the kinase domain, which is 
preceded by phosphorylation of the JMD residue, 
Y801(Solowiej J et al., 2009).  
Replacing the VEGFR2 JMD with the VEGFR1 
JMD reduces the kinase activity of VEGFR2 in vitro.  
Conversely, replacing the VEGFR1 JMD with the 
VEGFR2 JMD increases the kinase activity of 
VEGFR1(Gille H et al., 2000).  
These data suggest that the higher kinase activity of 
VEGFR2 relative to VEGFR1 may be partially 
explained by differences in the JMD. 
The kinase domain (KD; aa: 834-1162) is split by a 
70 amino acid insert (aa: 930-1000).  
Phosphorylation of the KD activation loop residues 
Y1054 and Y1059 is required for kinase 
activity(Kendall RL et al., 1999).  
Additional phosphorylation sites in the intracellular 
domain facilitate specific interactions of between 
VEGFR2 and signaling mediators, including PLC 
gamma, SHB, SCK, SHCA, GRB2, son of sevenless 
(SOS), and NCK. For further review, see S. Koch 
and L. Claesson-Welsh, 2012, and Claesson-Welsh 
and Welsh, 2013 (Claesson-Welsh L et al., 2013, 
Koch S et al., 2012). 
Co-receptors:  
Integrins, neuropilin-1, and CD146 promote 
VEGFR2 activation, and mediate VEGFR2 
activities, including endothelial cell migration, 
permeability, and angiogenesis.  
For more information, see Table 1 and Koch and 
Claesson-Welsh, 2012. 
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Alternative Isoforms:  
In 2009, Albuquerque et al. discovered that 
alternative splicing produces a soluble form of 
VEGFR2, present in mouse and human cornea 
(Albuquerque RJ et al., 2009). This isoform results 
from inclusion of the intron following exon 13 and 
results in a truncated product which migrates at 75 
kDa via western blot. This isoform contains only the 
extracellular domain of VEGFR2 and a unique C-
terminal sequence. Characterization of sVEGFR2 
revealed that it may play a role as an endogenous 
inhibitor of lymphoangiogenesis via antagonizing 
VEGF-C/VEGFR3 signaling (Albuquerque RJ et al., 
2009). 
Ligands:  
VEGF-A (Terman BI et al., 1992), VEGF-C (Joukov 
V et al., 1996), VEGF-D (Achen MG et al., 1998), 
and VEGF-E (M Meyer et al., 1999, Ogawa S et al., 
1998). VEGF-A is the primary endogenous ligand 
activating VEGFR2 signaling, while VEGF-C and 
VEGF-D signal mostly through VEGFR3. VEGF-E 
is encoded by the Orf virus and activates VEGFR2 
similarly to VEGF-A. Unlike VEGF-A, however, 
VEGF-E is a VEGFR2-exclusive ligand. 
Expression 
VEGFR2 is the principal VEGF receptor expressed 
on blood endothelial cells. Vegfr2-null mice die at 
E8.5 due to inadequate development of endothelial 
and hematopoietic cells(Shalaby F et al., 1995). 
Vegfr2 expression levels peak during embryonic 
angiogenesis and vasculogenesis (Millauer B et al., 
1993, Oelrichs RB et al., 1993). In adults, VEGFR2 
is expressed prominently on vascular endothelial 
cells, where it's expression is, in part, regulated by 
fibroblast growth factor signaling(Michael S. Pepper 
et al., 1998, Murakami M et al., 2011). Expression is 
also observed on hematopoietic stem cells and 
megakaryocytes(Casella I et al., 2003, Katoh O et al., 
1995, Larrivée B et al., 2003). 
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Full length VEGFR2 is localized on the plasma 
membrane and is internalized in a VEGF binding-
dependent manner (Koch S et al., 2012, 
Waltenberger J et al., 1994). Soluble VEGFR2 is 
secreted from the cell. 
Function 
VEGFR2 is the premier receptor mediating VEGF-
A activity on endothelial cells, where it functions to 
enhance proliferation, migration, and 
survival(Gerber HP et al., 1998, Jia H et al., 2004, 
Terman BI et al., 1992, Waltenberger J et al., 1994). 
Vegfr2 also promotes the survival of hematopoietic 
stem cells(Larrivée B et al., 2003). 
VEGFR2 is the principal VEGF receptor involved in 
vascular angiogenesis and the regulation of vascular 
permeability(Kowanetz M et al., 2006, Terman BI et 
al., 1992). VEGFR2 activity on vascular endothelial 
cells in tumors promotes tumor angiogenesis(K. H. 
Plate et al., 1993, Millauer B et al., 1994). For the 
effects of VEGFR2 signaling on different cell types, 
see Table 2. 
 VEGF Signaling Inhibitors:  
Strategies employed to target VEGF signaling are 
multifocal, consisting of monoclonal antibodies for 
both the ligands and VEGFRs, recombinant VEGFR 
extracellular domain fusion proteins (Table 3), and 




Increased VEGFR2 copy number has been identified 
in breast(Johansson I et al., 2012), non-small cell 
lung cancer (Yang F et al., 2011), and neurological 
malignancies (Blom T et al., 2010, Puputti M et al., 
2006).  
Missense mutations have been identified in 
hemangioma, leading to constitutive activation of 
VEGFR2 (Antonescu CR et al., 2009, Jinnin M et 
al., 2008, Walter JW et al., 2002). Wang et al., 2007, 
identified that polymorphisms in the VEGFR2 were 
associated with coronary heart disease (Wang Y et 
al., 2007) (Table 5).  
Glubb et al., 2011, characterized the significance of 
selected single nucleotide polymorphisms on 
VEGFR2 function and expression (Table 6).  
Of particular note, Glubb et al., 2011, identified that 
a SNP that results in the amino acid change Q472H, 
which was associated with increased VEGFR2 
activity, and was correlated with increased 
microvessel density in non-small cell lung cancer 
patients (Glubb DM et al., 2011) (Table 6). 
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Various Cancers (see Table) 
The expression VEGFR2 is increased by endothelial 
cells during tumor angiogenesis (K. H. Plate et al., 
1993, Millauer B et al., 1994). VEGFR2 expression 
has also been identified on myeloid-derived 
suppressor cells, where it functions in splenic MDSC 
expansion and the chemotaxis of MDSCs into 
tumors (Dineen et al., 2008, Huang Y et al., 2007, 
Roland CL et al., 2009). 
In addition to stromal cells, VEGFR2 expression by 
tumor cells has been identified in a variety of 
cancers, including bladder (Xia G et al., 2006), brain 
(Knizetova P et al., 2008, Nobusawa S1 et al., 2011, 
Puputti M et al., 2006, Yao X et al., 2013), breast 
(Ghosh S et al., 2008, Nakopoulou L et al., 2002, 
Yan JD et al., 2015), carcinoid (Silva SR et al., 
2011), cervical (Longatto-Filho A et al., 2009), 
colon (Giatromanolaki A et al., 2007, Takahashi Y 
et al., 1995), endometrial ID: 5045> 
(Giatromanolaki A et al., 2006), esophageal (Gockel 
I et al., 2008), gastric (Ozdemir F et al., 2006), head 
and neck (Lalla RV et al., 2003, Neuchrist C et al., 
2001), lung (Carrillo de Santa Pau E et al., 2009, 
Chatterjee S et al., 2013, Decaussin M et al., 1999, 
Seto T et al., 2006, Yang F et al., 2011), melanoma 
(Straume O et al., 2003), mesothelioma (Strizzi L et 
al., 2001), multiple myeloma (Giatromanolaki A et 
al., 2010), myeloid leukemia (Padró T et al., 2002), 
ovarian (Chen H et al., 2004, Spannuth WA et al., 
2009), pancreatic (Chung GG et al., 2006, Itakura J 
et al., 2000, von Marschall Z et al., 2000), prostate 
(Jackson MW et al., 2002, Köllermann J et al., 2001), 
renal cell carcinoma (Badalian G et al., 2007), 
squamous (Sato H et al., 2009), and thyroid 
(Rodrèguez-Antona C et al., 2010), (Table 7). 
In some cases, tumor cell expression of VEGFR2 
appears to play an important function in tumor 
progression and correlates with worse prognosis. For 
example, Yang et al. (2011) identified VEGFR2 
copy number gains (CNG) in 32% of tumors, which 
was associated with increased VEGFR2 protein, 
tumor angiogenesis, and correlated with poor 
prognosis(Yang F et al., 2011). Furthermore, 
Chatterjee et al. (2013) identified that the levels of 
VEGF/VEGFR2 binding on tumor cells strongly 
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correlated with tumor angiogenesis, and selective 
VEGFR2 inhibition had a significant combinatorial 
effect with MEK inhibitors in reducing tumor 
growth in preclinical models of NSCLC(Chatterjee 
S et al., 2013). 
Yan et al. (2015) found that VEGFR2 expression by 
breast tumor cells was significantly correlated with 
increased lymph node metastasis, epithelial to 
mesenchymal transition (EMT) marker expression, 
and reduced overall survival(Yan JD et al., 2015). 
For further review of expression and function of 
VEGFR2 in different cancers, see Table 7 and Goel 
and Mercurio, 2013(Goel HL et al., 2013). 
Coronary Heart Disease 
Wang et al., 2007, identified that polymorphisms in 
the VEGFR2 were associated with coronary heart 
disease (Wang Y et al., 2007) (Table 5). 
Hemangioma 
Missense mutations have been identified in 
hemangioma, leading to constitutive activation of 
VEGFR2 (Antonescu CR et al., 2009, Jinnin M et 
al., 2008, Walter JW et al., 2002). 
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